The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

For the past several years, the halls of the Las Vegas Convention Center have been lousy with AR/VR/XR smart glasses. While ...

Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.

BMO Capital downgraded 4D Molecular (FDMT) to Market Perform from Outperform with a price target of $15, down from $40. 4D-150 durability in ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...

Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...